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Background: The treatment of migraine headache is challenging given the lack of a standardized approach to care,
unsatisfactory response rates, and medication overuse. Neuromodulation therapy has gained interest as an alternative
to pharmacologic therapy for primary headache disorders. This study investigated the effects of non-invasive vagus
nerve stimulation (nVNS) in patients with high-frequency episodic migraine (HFEM) and chronic migraine (CM).
Findings: In this open-label, single-arm, multicenter study, patients with HFEM or CM self-treated up to 3
consecutive mild or moderate migraine attacks that occurred during a 2-week period by delivering two 120-s
doses of nVNS at 3-min intervals to the right cervical branch of the vagus nerve. Of the 50 migraineurs enrolled
(CM/HFEM: 36/14), 48 treated 131 attacks. The proportion of patients reporting pain relief, defined as a ≥50 %
reduction in visual analog scale (VAS) score, was 56.3 % at 1 h and 64.6 % at 2 h. Of these patients, 35.4 % and
39.6 % achieved pain-free status (VAS = 0) at 1 and 2 h, respectively. When all attacks (N = 131) were considered,
the pain-relief rate was 38.2 % at 1 h and 51.1 % at 2 h, whereas the pain-free rate was 17.6 % at 1 h and 22.9 %
at 2 h. Treatment with nVNS was safe and well tolerated.
Conclusion: Non-invasive vagus nerve stimulation may be effective as acute treatment for HFEM or CM and may
help to reduce medication overuse and medication-associated adverse events.
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Introduction
Migraine, a highly disabling neurological disorder, is
characterized by recurrent moderate to severe attacks
associated with vegetative symptoms [1]. Patients with
frequent attacks may overuse medications, leading to
migraine chronification and medication-overuse head-
ache. During the last decade, neuromodulatory ap-
proaches have been developed for the management of
headaches that do not respond adequately to therapy [2].
Invasive neurostimulation targeting the hypothalamus,
sphenopalatine ganglia, and occipital, supraorbital, or auri-
culotemporal nerves has yielded encouraging results [2].
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provided the original work is properly creditedapproved for medically refractory epilepsy and depression
[3, 4] and has demonstrated clinical benefit in intractable
migraine with comorbid depression [5]. Experimentally,
VNS has modulated neurotransmitters, influenced cere-
bral metabolism [6] and blood flow [7] in the limbic sys-
tem and pain matrix regions, and exerted antinociceptive
effects in acute and inflammatory pain models [8, 9]. Pro-
posed mechanisms of VNS in pain pathways may involve
modulation of excess glutamate levels in the trigeminal
nucleus caudalis, effects on pain control centers, and
modulation of cortical excitability [9–11].
A non-invasive VNS device (nVNS; gammaCore®) has
been developed and is CE-marked for acute and prophy-
lactic treatment of primary headache disorders including
migraine and cluster headache [12]. In a recent open-
label study of 30 episodic migraineurs, nVNS was effect-
ive in the acute treatment of migraine attacks and re-
sulted in a 2-h pain-free rate of 22 % [11]. To further
examine the clinical benefit of nVNS reported in therticle distributed under the terms of the Creative Commons Attribution License
hich permits unrestricted use, distribution, and reproduction in any medium,
.
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nVNS on migraine attacks at 1 and 2 h in a larger pa-
tient population with high-frequency episodic migraine
(HFEM; ≥8 headache days per month, with or without
aura) or chronic migraine (CM; ≥15 headache days per
month) [1, 13].
Methods
In this open-label, single-arm, multicenter study, 50 pa-
tients aged 18 to 65 years who were experiencing HFEM
or CM [1, 13] were consecutively enrolled between Feb-
ruary 1, 2013, and October 1, 2013, at the Headache and
Pain Unit of the IRCCS San Raffaele Pisana in Rome, Italy,
and the Headache Center of the Carlo Besta Neurological
Institute and Foundation in Milan. The study protocol
was approved by the San Raffaele Pisana institutional re-
view board (10/2013), and all patients who were enrolled
in the study provided written informed consent. The study
population excluded patients with a history of cerebrovas-
cular, cardiovascular, or atherosclerotic disease (including
carotid artery disease, heart arrhythmias, or syncope) or
any significant neurological or systemic disorder and pa-
tients with an implanted electrical device.
At monthly educational meetings involving groups of
3 to 6 patients as well as neurologists and counselors,
patients were instructed on how to use the nVNS device
and were invited to describe their experiences with mi-
graine and how they usually managed migraine attacks.
Patients received basic information on vagus nerve
physiology and vagal neurostimulation and watched a
video demonstrating how nVNS is believed to work.
Prior to study initiation, patients were actively encour-
aged to use nVNS and received training on the proper
use of the device from a physician and via an instruc-
tional video.
Patients were instructed to use nVNS to self-treat up
to three consecutive migraine attacks that occurred over
a 2-week period. For each migraine attack, patients de-
livered two 120-s doses of electrical stimulation at 3-min
intervals to the right cervical branch of the vagus nerve
within 20 min of the onset of mild or moderate pain.
Patients were allowed to take a rescue medication if
they perceived no reduction in pain 2 h after nVNS
treatment. Pain severity was rated using a 0- to 10-cm
visual analog scale (VAS) score (0 cm, no pain; 1-3 cm,
mild; 4-6 cm, moderate; 7-10 cm, severe) at baseline, 1 h,
and 2 h. Patients recorded pain severity in a headache
diary, along with symptoms of nausea, photophobia,
phonophobia, and functional disability (at baseline and
2 h); the use of rescue medications and adverse events
were also recorded.
Pain relief was defined as a ≥50 % reduction in VAS
score. Pain-free status was defined as a VAS score of 0. The
primary end point was pain-free status at 2 h. Secondaryend points were pain relief at 1 and 2 h; pain-free status at
1 h; absence of nausea, photophobia, and phonophobia at
2 h; complete recovery from functional disability at 2 h;
use of rescue medication; safety; tolerability; and end-of-
study assessment of patients’ satisfaction (5-point scale: 1,
very dissatisfied, to 5, very satisfied) with treatment, their
willingness to use the device in the future, and their
perceptions regarding the safety of nVNS. Descriptive sta-
tistics (ie, mean [standard deviation]) were used to de-
scribe categorical data; no other statistical analyses were
performed.
Results
We enrolled 50 patients (female/male: 40/10) affected by
CM (n = 36) and HFEM (n = 14) (Table 1). Two patients
with CM did not treat any migraine attacks; the
remaining 48 patients treated a total of 131 attacks. Spe-
cifically, 30 patients with CM and 6 with HFEM treated
3 attacks each; 4 patients with CM and 7 with HFEM
treated 2 attacks each; and 1 patient with HFEM treated
1 attack. After nVNS, 27 of 48 patients (56.3 %) reported
pain relief at 1 h; of these patients, 35.4 % (n = 17) were
pain free. Thirty-one patients (64.6 %) reported pain re-
lief at 2 h, of which 39.6 % (n = 19) were pain free (Fig. 1).
For all 131 migraine attacks, pain relief was reported for
38.2 % (50 of 131) of attacks at 1 h and for 51.1 % (67 of
131) at 2 h; pain-free status was reported for 17.6 % (23
of 131) of attacks at 1 h and for 22.9 % (30 of 131) of at-
tacks at 2 h (Fig. 2). Achievement of pain-free status at 1
and 2 h for at least 1 attack was experienced in 33.3 %
(11 of 33) of patients treating 3 attacks and 41.7 % (5 of
12) of patients treating 2 attacks (5 of 12).
When comparing efficacy of nVNS among patients
with CM versus HFEM, we found a consistent trend
toward greater efficacy in patients with HFEM. The
proportion of patients reporting pain relief after
nVNS was greater in HFEM at 1 h (HFEM, 71.4 %
[10 of 14]; CM, 50.0 % [17 of 34]) and at 2 h (HFEM,
78.6 % [11 of 14]; CM, 58.8 % [20 of 34]); achieve-
ment of pain-free status was also greater in HFEM at
1 h (HFEM, 50.0 % [7 of 14]; CM, 29.4 % [10 of 34])
and at 2 h (HFEM, 50.0 % [7 of 14]; CM, 35.5 % [12
of 34]) (Fig. 3). A similar trend was seen for all 131
attacks. A greater proportion of HFEM attacks
achieved pain relief at 1 h (HFEM, 45.5 % [15 of 33];
CM, 35.7 % [35 of 98]) and 2 h (HFEM, 60.6 % [20 of
33]; CM, 48.0 % [47of 98]); more attacks achieved
pain-free status at 1 h (HFEM, 30.3 % [10 of 33]; CM,
13.3 % [13 of 98]) and at 2 h (HFEM, 33.3 % [11 of
33]; CM, 19.4 % [19 of 98]) (Fig. 4).
The proportion of patients who responded to nVNS
in ≥ 50 % of the migraine attacks at 2 h was 62.5 %
for pain relief (78.6 % in HFEM, 55.9 % in CM) and
33.3 % for pain free (50 % in HFEM, 26.5 % in CM).
Table 1 Demographic and baseline characteristics of study population
All HFEM CM
N = 50 n = 14 n = 36
Mean (SD) age, y 43.2 (11.3) 43.2 (12.3) 43.3 (10.8)
Female, n (%) 40 (80) 11 (78.6) 29 (80.5)
Mean (SD) disease duration, y 29.7 (11.2) 30.4 (13.5) 29.5 (10.2)
Mean (SD) number of migraine days per month 15.4 (5.6) 7.9 (2.3) 18.3 (3.3)
Allodyniaa, n (%) 18 (36) 4 (28.6) 14 (38.9)
Concomitant prophylaxis, n (%) 39 (78) 10 (71.4) 29 (80.6)
Migraine Type, n (%)
Migraine without aura 14 (28) 14 (100) 0
Medication overuse headache 5 (10) 0 5 (13.9)
Chronic migraine 36 (72) 0 36 (100)
Migraine Pain Location, n (%)
Unilateral 28 (56) 10 (71.4) 18 (50)
Bilateral 18 (36) 3 (21.4) 15 (41.7)
Unilateral/bilateral 4 (8) 1 (7.2) 3 (8.3)
Duration of Migraine Attacks, n (%)
≤24 h 17 (34) 5 (35.7) 12 (33.3)
25-48 h 8 (16) 2 (14.3) 6 (16.7)
>48 h 25 (50) 7 (50) 18 (50)
CM chronic migraine, HFEM high-frequency episodic migraine; SD standard deviation
aAllodynia was assessed using the Allodynia Symptom Checklist
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(87 of 131) of attacks; freedom from photophobia and
phonophobia was reported in 76.3 % (100 of 131) and
77.1 % (101 of 131) of attacks, respectively. Complete re-
covery from functional disability at 2 h was reported in
35.1 % of attacks. Rescue medications were taken in
53.4 % (70 of 131) of the attacks.
No major adverse events were reported. Mild tingling
or pricking sensations at the stimulation site, reported
by 67 % (32 of 48) of patients, was the only adverse
event associated with nVNS. Nearly half of the patients
(45.8 %; 22 of 48) reported satisfaction (ie, satisfied or
very satisfied) with treatment and were willing to use theFig. 1 Response to nVNS treatment in 48 Migraineurs. Abbreviations:
nVNS, non-invasive vagus nerve stimulationdevice in the future. All patients considered nVNS treat-
ment to be safe.
Discussion
Results from the present study validate prior evidence
that shows nVNS is effective for the acute treatment of
migraine attacks in patients with HFEM or CM [11].
With enrollment of a larger (N = 50), more severely af-
fected population who experienced more migraine at-
tacks (N = 131), our research extends data from previous
studies that showed a 2-h pain-free response of 22 %
[11]. More than half of the patients (64.6 %) in our study
experienced pain relief at 2 h, and 39.6 % were pain freeFig. 2 Response to nVNS treatment in 131 Migraine Attacks.
Abbreviations: nVNS, non-invasive vagus nerve stimulation
Fig. 3 Response to nVNSat 1 and 2 Hours by Patient Type
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with 56.3 % of patients experiencing pain relief, including
35.4 % of patients who were pain free. Additionally, we
discovered that patients with a lower frequency of at-
tacks (ie, HFEM; 8-14 headache days per month)Fig. 4 Response to nVNSat 1 and 2 Hours by Migraine Attack Typeappeared to achieve a better response than those with
a higher frequency of attacks (CM; ≥15 headache days
per month). This finding represents an early treatment
paradigm in which nVNS was administered when mi-
graine pain was mild or moderate rather than severe. Al-
though this paradigm may increase the placebo effect, it
was selected because headaches in CM are typically re-
ported to be mild or moderate compared with more se-
vere headaches in episodic migraine [14, 15]. Moreover,
persistent activity of pain-processing regions within the
brain and low expectation of success in patients with CM
may mitigate any placebo effect [16]. Other limitations of
this study are the open-label design, lack of control group,
and short duration. Moreover, larger studies are re-
quired. However, studies of nVNS in migraine [11] and
cluster headache [17] have also implemented a short-
term, single-arm, open-label design to demonstrate the
feasibility of nVNS in real-world clinical practice. Prelim-
inary data from large-scale, multicenter, randomized, con-
trolled studies of nVNS in CM [18] and chronic cluster
headache [19] have further corroborated its clinical
benefit.
We investigated the benefit of nVNS in a real-world
clinical setting; findings from this study will expand the
body of clinical evidence on nVNS to the HFEM/CM
population whose pain is difficult to manage. Further-
more, we implemented intensive educational training to
ensure treatment adherence, assessed headache response
at a short interval (ie, 1 h), and evaluated treatment sat-
isfaction. Our data confirm that nVNS is well tolerated
and safe and is associated with treatment satisfaction
and therapeutic adherence. From a risk-benefit perspec-
tive, nVNS therapy achieved pain relief without serious
side effects, which may decrease patients’ reliance on
migraine medications and, in turn, lower the risk of
medication overuse.
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